Skip to content

Randomized Controlled Trial Comparing Embryonic Quality in rFSH Versus hMG in IVF Protocol With GnRH Antagonist

Phase 4 Study Comparing Recombinant Follicle Stimulating Hormone (rFSH) or Ultra-pure to HMG in Patients Submitted to IVF Using Gnrh Antagonist

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02412904
Enrollment
188
Registered
2015-04-09
Start date
2014-01-31
Completion date
2014-12-31
Last updated
2015-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

follicular stimulating hormone, human menopausal gonadotrophin, Recombinant follicular stimulating hormone (rFSH), Gonadotrophin releasing hormone (GnRH) antagonists, GnRH agonist, in vitro fertilization, controled ovarian stimulation, number of mature oocytes

Brief summary

rFSH and HMG are both used to controlled ovarian stimulation for patients submitted to IVF. However, there is a debate in the literature which one is better to induce ovulation in patients receiving GnRH antagonist to block premature Luteinizing Hormone (LH) secretion. The investigators propose a Randomized Clinical Trial (RCT) to investigate the differences among recombinant FSH and HMG in patients submitted to IVF using GnRH antagonists.

Detailed description

To compare embryonic quality and other clinical outcomes when using human menopause gonadotropin (hMG) or recombinant follicle stimulating hormone (rFSH) to the ovarian stimulation in IVF cycles with the GnRH antagonist protocol. Design: open randomized single center study with infertile patients submitted to IVF comparing IVF outcomes between hMG and rFSH when controlled with GnRH antagonist. Setting: A single private center of reproductive medicine in association with Universidade Federal do Rio Grande do Sul. Patients: Infertile women with normal ovarian reserve with IVF indication. Intervention: The patients were randomized in two groups, 85 received rFSH and 83 received hMG to ovulation induction, both groups used GnRH antagonist to prevent ovulation. Main Outcome Measure: Total embryonic score and best embryonic score. Secondary outcomes: Total dose of gonadotropins, number and size of follicles in the end of the stimulation, number of mature oocytes, number of embryos, pregnancy rates.

Interventions

DRUGrFSH

the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days

DRUGHMG

the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days

Sponsors

Center for Human Reproduction
CollaboratorOTHER
Hospital de Clinicas de Porto Alegre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* 25 to 40 y * infertile * submitted to IVF * no hormonal disease * normal FSH (\< 10) * anti-mullerian hormone (AMH) \> 1 ng and \< 10 ng * both ovaries * only first or second IVF

Exclusion criteria

* thyroid-stimulating hormone (TSH), prolactin (PRL) altered * endometrioma * ovarian tumor or cysts * previous Ovarian Hyperstimulation Syndrome (OHSS) * severe male factor

Design outcomes

Primary

MeasureTime frameDescription
Embryo quality - score of embryo quality in the model od the Graduated Embryo Score (GES)3 to 5 days after the ovarian punctionThe embryo evaluation will be performed on day three after fertilization based on the Graduated Embryo Score (GES). It will be performed three evaluations occurring at 16 - 18 hours, 25 - 27 hours and 64 - 67 hours post insemination, by the same embryologist (DS) The score is composed by the following criteria: nucleolar alignment along pronuclear axis, regular cleavage and degree of fragmentation at the first cell division, and cell number and morphology on day 3 after fertilization. The score ranges from 20 to 100 per embryo.

Secondary

MeasureTime frame
number of embryos3 to 5 days after the ovarian punction
number of follicles graduated by size in groups of 13-14mm; 15-16mm and more than 17mm10 to 13 days after the IVF protocol starts
total number of units of gonadotrophins used to ovarian stimulation10 to 13 days after the IVF protocol starts
number of oocytes retrieved (MII)10 to 13 days after the IVF protocol starts

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026